DAUNORUBITEC Injection 1's
Netmeds First Membership
Quick Links
Introduction About DAUNORUBITEC INJECTION
DAUNORUBITEC INJECTION is used for inducing remissions of acute myelogenous and lymphocytic leukaemias and for the management of acute lymphocytic leukaemia and acute myloid leukaemia in children, as part of a combination regimen. DAUNORUBITEC INJECTION contains Daunorubicin which belongs to the group of medicines known as Chemotherapeutic agents. It works by attacking and destroying the abnormal white blood cells which are present in the person with leukaemia.
DAUNORUBITEC INJECTION is not recommended in patients who are recently exposed to, or with existing, chicken pox or herpes zoster, persistent myelosuppression, have severe infection, severe hepatic or renal function impairment. DAUNORUBITEC INJECTION should be used with caution if you had radiation therapy for the chest, have or had gout. Consult your doctor for advice before receiving the medicine. DAUNORUBITEC INJECTION should not be used during pregnancy unless the clinical condition of the woman requires treatment with DAUNORUBITEC INJECTION and justifies the potential risk to the foetus. It is not recommended for use in breastfeeding women.
Your doctor will administer the right dose depends on your child’s age, body weight and severity of the disease. DAUNORUBITEC INJECTION should be used with caution in elderly patients with inadequate bone marrow reserves to old age. The most common side effects of receiving DAUNORUBITEC INJECTION are nausea, vomiting or diarrhoea. If any of these side effects worsen, contact your doctor immediately.
Uses Of DAUNORUBITEC INJECTION
It is used for:
- inducing remissions of acute myelogenous and lymphocytic leukaemias
- the management of acute lymphocytic leukaemia and acute myloid leukaemia in children, as part of a combination regimen
How DAUNORUBITEC INJECTION Works
DAUNORUBITEC INJECTION contains Daunorubicin which is an anthracycline glycoside antibiotic and potent antileukaemic agent. The exact mechanism of antineoplastic action is uncertain but may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. It is most active in the S-phase of cell division but is not cycle phase specific.
How to use DAUNORUBITEC INJECTION
DAUNORUBITEC INJECTION will be administered by your doctor or nurse by intravenously. It is not recommended for intramuscular administration. Your doctor will administer the correct dose and duration for you depending on your age, body weight and disease condition.
Side Effects Of DAUNORUBITEC INJECTION
Common
- nausea
- vomiting
- inflammation of the bowel
- skin rash
- sores in the mouth or lips
Stop receiving DAUNORUBITEC INJECTION and consult your doctor immediately, if you experience the following:
- pain or swelling around the vein where the medicine has been injected
- red face (where the medicine is injected)
- fever, chills and other signs of infection
- severe infection
- low blood pressure
- difficult in breathing, swelling in the feet or legs, uneven or fast heartbeat, black or tarry bowel motions
- unusual bleeding or bruising
How To Manage Side Effects
Diarrhea
Drink lot of fluids, such as water to keep yourself hydrated. Avoid eating high-fat or spicy foods. Try to avoid taking any medicine on your own to manage diarrhoea and consult your doctor if the symptom gets worse.
Nausea And Vomiting
Try and take the medicine with, or just after meals. Stick to simple meals. Avoid eating oily or spicy foods. Consult your doctor if your symptom gets worse.
Warning & Precautions
Pregnancy
Consult your doctorDAUNORUBITEC INJECTION should not be used during pregnancy unless the clinical condition of the woman requires treatment with DAUNORUBITEC INJECTION and justifies the potential risk to the foetus. Consult your doctor before receiving.
Breastfeeding
ContraindicatedIt is unknown whether DAUNORUBITEC INJECTION are excreted in human milk, hence it is contraindicated during breast-feeding. Consult your doctor before receiving
Driving and Using Machines
Use with CautionDo not drive or handle any heavy machines, since the use of DAUNORUBITEC INJECTION may cause seizures or visual disturbances in some individuals.
Kidney
ContraindicatedDAUNORUBITEC INJECTION is not recommended if you have severe renal impairment. Consult your doctor before receiving.
Liver
ContraindicatedDAUNORUBITEC INJECTION is not recommended if you have severe hepatic impairment. Consult your doctor before receiving.
Allergy
ContraindicatedDo not receive DAUNORUBITEC INJECTION if you are allergic to Daunorubicin or any other ingredients of this medicine.
Heart Disease
ContraindicatedDAUNORUBITEC INJECTION is not recommended if you have myocardial insufficiency, had recent myocardial infarction or severe arrhythmias. Consult your doctor before receiving.
Use In Pediatrics
Consult your doctorYour doctor will administer the right dose depends on your child’s age, body weight and severity of the disease.
Use In Geriatrics
Use with CautionDAUNORUBITEC INJECTION should be used with caution in elderly patients with inadequate bone marrow reserves to old age.
Others
DAUNORUBITEC INJECTION is not recommended to receive if you:
- recently exposed to, or with existing, chicken pox or herpes zoster
- have persistent myelosuppression
- have severe infection
- severe hepatic or renal function impairment
Before receiving DAUNORUBITEC INJECTION, inform your doctor if you:
- had radiation therapy for the chest
- have or had gout
Interactions
A. Drug-Drug Interactions:
- Anti-cancer agents (Ex. Cisplatin, taxanes, 5-fluorouracil, calcium channel blockers)
- Anticonvulsants (Ex. Chloramphenicol, diphenylhydantoin)
- Anti-TB agents (Ex. Rifampicin)
- Live attenuated vaccines
Overdosage:
DAUNORUBITEC INJECTION will be administered by your doctor or nurse, so it is unlikely to receive an overdose. It may cause acute myocardial degeneration within 24 hours and severe myelosuppression within 10 - 14 days. The occurrence of cardiac damage up to several months after an overdose has been reported for anthracyclines.
Synopsis
| Drug | : | Daunorubicin |
| Pharmacological Category | : | Anthracycline class of antibiotics |
| Therapeutic Indication | : | Inducing remissions of acute myelogenous and lymphocytic leukaemias, Management of acute lymphocytic leukaemia and acute myloid leukaemia in children, as part of a combination regimen |
| Dosage Forms | : | Injection |
More Information
Storage
- Keep DAUNORUBITEC INJECTION out of reach from children
- Store below 25°C
FAQs About DAUNORUBITEC INJECTION
Q: What is DAUNORUBITEC INJECTION used for?
A: DAUNORUBITEC INJECTION is used for inducing remissions of acute myelogenous and lymphocytic leukaemias and for the management of acute lymphocytic leukaemia and acute myloid leukaemia in children, as part of a combination regimen.
Q: What precautions should I take while taking DAUNORUBITEC INJECTION?
A: DAUNORUBITEC INJECTION should be used with caution if you had radiation therapy for the chest, have or had gout. Consult your doctor for advice before receiving the medicine.
Q: Is DAUNORUBITEC INJECTION safe during pregnancy?
A: No. DAUNORUBITEC INJECTION should not be used during pregnancy unless the clinical condition of the woman requires treatment with DAUNORUBITEC INJECTION and justifies the potential risk to the foetus. Consult your doctor before receiving.
Q: Is DAUNORUBITEC INJECTION toxic to the liver?
A: Yes. The hepatic injury due to DAUNORUBITEC INJECTION varies in severity from mild, transient and asymptomatic liver enzyme elevations to acute liver failure due to sinusoidal obstruction syndrome. Consult your doctor before receiving the medicine.
Q: What are the side effects of DAUNORUBITEC INJECTION?
A: The common side effects of receiving DAUNORUBITEC INJECTION are nausea, vomiting, inflammation of the bowel, skin rash and sores in the mouth or lips.
Q: How is DAUNORUBITEC INJECTION typically administered?
A: DAUNORUBITEC INJECTION is administered intravenously (into a vein) and the dose depends on several factors, including the condition being treated, the size of the patient, the particular treatment regimen being used, and the overall health of the patient. During administration, if the medicine escapes from the vein in which it is being given, it can cause serious damage to tissues that it may come in contact with. Although patients will be monitored for this, patients should notify their healthcare provider immediately if they experience pain, redness or swelling at the area of intravenous administration.
Q: How are patients monitored?
A: Patients will usually have scheduled meetings during management with DAUNORUBITEC INJECTION to assess side effects and response to therapy. Typically, blood will be drawn to determine levels of blood cells, electrolytes, and monitor function of metabolism and some organs such as the liver and kidneys. Heart function will be monitored prior to treatment and possibly during treatment, as DAUNORUBITEC INJECTION may cause damage to the heart.
Q: Will I receive DAUNORUBITEC INJECTION treatment in the hospital or in an outpatient setting?
A: Your healthcare team may decide to administer DAUNORUBITEC INJECTION in an outpatient setting based on the severity of the disease, overall health, and how close you live to an infusion center. Your healthcare team will determine what is best for you.
References
1. Tabinda Saleem, Anup Kasi. Daunorubicin. National library of medicine. Revised on August 28, 2023. [Accessed on August 23rd, 2024] https://www.ncbi.nlm.nih.gov/books/NBK559073/
2. Zentiva. Electronic Medicines Compendium (EMC). [Revised in March 17, 2020] [Accessed on August 23rd, 2024] https://www.medicines.org.uk/emc/product/4004/smpc/print
Useful Diagnostic Tests
- Total IGE
- Fish-Multiple Myeloma
- Cancer Screening Package For Male
- Cancer Screening Package For Female
Author Details
